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Correction
Following the publication of our article [1], we noticed
an error regarding the dosage of vitamin B12. In the
manuscript, we reported that the daily dosage of vitamin
B 1 2w o u l db e0 . 4m g ,w h e ni nf a c tt h ed o s a g eo fv i t a -
min B12 used in the B-VITAGE trial is 0.5 mg per day.
In the abstract:
The B-VITAGE trial is a 12-month randomized, dou-
ble-blind, placebo-controlled trial of daily citalopram (20
to 40 mg) plus B12(0.4 mg), B6 (25 mg) and folic acid (2
m g )o rc i t a l o p r a m( 2 0t o4 0m g )p l u sp l a c e b of o rt h e
treatment of depression in later life.
Should read
The B-VITAGE trial is a 12-month randomized, dou-
ble-blind, placebo-controlled trial of daily citalopram (20
to 40 mg) plus B12(0.5 mg), B6 (25 mg) and folic acid (2
m g )o rc i t a l o p r a m( 2 0t o4 0m g )p l u sp l a c e b of o rt h e
treatment of depression in later life.
In the “Intervention and Blinding” section:
Eligible participants will be randomly allocated to
treatment with citalopram plus 400 μgv i t a m i nB 12,2
mg folic acid and 25 mg B6 or citalopram plus placebo.
Should read
Eligible participants will be randomly allocated to
treatment with citalopram plus 500 μgv i t a m i nB 12,2
mg folic acid and 25 mg B6 or citalopram plus placebo.
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